PhD Candidate | Chinese PLA General Hospital | China
Dr. Zhi Cao is a PhD candidate at the Chinese People’s Liberation Army General Hospital whose research profile reflects strong scientific rigor, innovation, and clinical relevance in cancer immunotherapy and neuroscience. Her authorship in a high-impact Nature Communications article demonstrates leadership in advancing translational oncology, where she contributed to pioneering preclinical and phase I clinical evidence showing that inhibition of glycosphingolipid synthesis using eliglustat can enhance the efficacy of immune checkpoint inhibitors in advanced cancers, a finding with direct implications for overcoming tumor immune resistance. This work, published in a Q1 journal with a high impact factor, highlights her ability to bridge molecular mechanisms with early-phase clinical application. Complementing this, her comprehensive review in Frontiers in Immunology systematically elucidates the synthesis, biological functions, and therapeutic potential of glycosphingolipids, reinforcing her expertise in tumor immunometabolism and immune modulation while guiding future therapeutic strategies. Beyond oncology, her interdisciplinary strength is evident in her Q1 Brain Research publication, where she applied single-cell molecular analyses to identify target cells and signaling pathways involved in conditioned fear memory, demonstrating technical versatility and strong analytical skills across biomedical domains. Her stated research interests in CAR-T cell immunotherapy and tumor therapy mechanisms align closely with global priorities in precision medicine and next-generation cancer treatments. Collectively, her publication record, impact factor profile, methodological depth, and translational focus indicate a researcher with significant promise and originality, making her a strong and credible candidate for recognition associated with a Best Research Article or similar high-level academic distinction.
Profile: ORCID
Featured Publications
Dong, L., Cao, Z., Chen, M., et al. (2024). Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: Preclinical evidence and phase I clinical trial. Nature Communications, 15.
Dong, L., Cao, Z., Han, W., & Wu, Z. (2025). Synthesis, function, and therapeutic potential of glycosphingolipids. Frontiers in Immunology, 16.
Shen, M., Cao, Z., Tian, R., et al. (2023). Single-cell molecular alterations reveal target cells and pathways of conditioned fear memory. Brain Research, 1798.
Dr. Zhi Cao’s research advances global cancer innovation by uncovering novel immunometabolic mechanisms that enhance the effectiveness of immunotherapies and CAR-T strategies. By bridging molecular discovery with early-phase clinical translation, her work accelerates precision oncology solutions with the potential to improve patient outcomes worldwide.